Needham Reiterates Buy on OrthoPediatrics, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson reiterated a Buy rating on OrthoPediatrics (NASDAQ:KIDS) and maintained a $37 price target.

March 07, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson reiterated a Buy rating on OrthoPediatrics and maintained a $37 price target.
The reiteration of a Buy rating and maintenance of a $37 price target by a reputable analyst like Mike Matson from Needham is likely to instill confidence among investors and could positively influence OrthoPediatrics' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100